Affirmed Therapeutics BV (NASDAQ:AFMD) shares shot up 1.8% during trading on Wednesday . The company traded as high as $2.84 and last traded at $2.83, with a volume of 52,583 shares changing hands. The stock had previously closed at $2.78.

A number of research firms have recently commented on AFMD. Jefferies Group dropped their price objective on Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Thursday, May 19th. Leerink Swann downgraded Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $8.00 to $3.00 in a report on Friday, August 12th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Affirmed Therapeutics BV in a report on Wednesday, May 18th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Affirmed Therapeutics BV presently has a consensus rating of “Buy” and an average target price of $8.63.

The firm’s 50-day moving average is $2.83 and its 200 day moving average is $3.42. The company’s market cap is $91.42 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last released its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by $0.05. During the same quarter last year, the business posted ($0.19) EPS. The company earned $2.07 million during the quarter, compared to analyst estimates of $2.10 million. The business’s quarterly revenue was down 6.4% on a year-over-year basis. Analysts predict that Affirmed Therapeutics BV will post ($1.12) earnings per share for the current fiscal year.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.